Resverlogix Announces Participation in Upcoming Conferences

Thursday, November 2, 2017 12:00 PM UTC

CALGARY, Alberta, Nov. 02, 2017 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce the Company’s participation in the following upcoming industry conferences.

• American Society of Nephrology – ASN 2017 Annual Meeting
Location:	New Orleans, LA.
Date:	November 3^rd, 2017
Poster 1:	“Analysis of the Plasma Proteome Reveals Dysregulation of Molecular Pathways in Patients with Stage 4 Chronic Kidney Disease”
Presentation Time:	10:00am - 12:00pm CT

Date:	November 4^th, 2017
Poster 2:	“Apabetalone (RVX-208) Impacts Key Markers and Pathways Associated with Chronic Kidney Disease in Patients with Severe Renal Impairment”
Presentation Time:	10:00am - 12:00pm CT
Meeting Link:	LINK

• BIO-Europe 2017
Location:	Berlin, Germany.
Date:	November 7^th, 2017
Presentation Time:	4:45pm CEST
Presenting:	Mr. Donald McCaffrey, President and Chief Executive Officer
Conference Link:	LINK

• American Heart Association – AHA Scientific Sessions 2017
Location:	Anaheim, CA
Date:	November 13^th, 2017
Poster:	“Apabetalone Downregulates Factors That Promote Vascular Calcification and Contribute to Cardiovascular Events”
Presentation Time:	10:30am PT
Meeting Link:	LINK

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: [email protected]
Phone: 403-254-9252